431.86
price down icon0.56%   -2.44
pre-market  Vorhandelsmarkt:  438.00   6.14   +1.42%
loading

Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten

pulisher
Apr 07, 2026

Vertex Pharmaceuticals Inc stock: New Halozyme deal signals pipeline push - AD HOC NEWS

Apr 07, 2026
pulisher
Apr 07, 2026

Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications - GlobeNewswire Inc.

Apr 07, 2026
pulisher
Apr 07, 2026

Vertex taps Halozyme and its recently acquired Elektrofi tech in $15M drug delivery deal - Fierce Pharma

Apr 07, 2026
pulisher
Apr 07, 2026

Vertex Pharma in pact with Halozyme for Hypercon (VRTX:NASDAQ) - Seeking Alpha

Apr 07, 2026
pulisher
Apr 07, 2026

Halozyme (HALO) Unveils Partnership with Vertex for Drug Deliver - GuruFocus

Apr 07, 2026
pulisher
Apr 07, 2026

Halozyme, Vertex Pharmaceuticals Enter Exclusive Collab & License Agreement - Contract Pharma

Apr 07, 2026
pulisher
Apr 07, 2026

Halozyme announces global collaboration and license agreement with Vertex Pharmaceuticals for Hypercon(TM) technology - marketscreener.com

Apr 07, 2026
pulisher
Apr 07, 2026

Halozyme Announces Global Collaboration And License Agreement With Vertex Pharmaceuticals For Hypercon™ Technology - TradingView

Apr 07, 2026
pulisher
Apr 07, 2026

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology - prnewswire.com

Apr 07, 2026
pulisher
Apr 06, 2026

Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Apr 06, 2026
pulisher
Apr 06, 2026

Vertex Pharmaceuticals Incorporated (VRTX) stock price, news, quote and history - Yahoo Finance UK

Apr 06, 2026
pulisher
Apr 06, 2026

Vertex to Announce First Quarter 2026 Financial Results on May 4th - businesswire.com

Apr 06, 2026
pulisher
Apr 06, 2026

Biotech layoffs pick back up as 14 companies cut 745 jobs in Q1 - The Business Journals

Apr 06, 2026
pulisher
Apr 05, 2026

Best Biotech Stocks To Follow NowApril 5th - MarketBeat

Apr 05, 2026
pulisher
Apr 04, 2026

CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 04, 2026
pulisher
Apr 03, 2026

Insider Sell: Joy Liu Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus

Apr 03, 2026
pulisher
Apr 03, 2026

Vertex Pharmaceuticals EVP Sells $439,288 in Stock - National Today

Apr 03, 2026
pulisher
Apr 03, 2026

Insider Selling: Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells $439,288.26 in Stock - MarketBeat

Apr 03, 2026
pulisher
Apr 03, 2026

Vertex (VRTX) legal chief sells 978 shares under 10b5-1 plan - Stock Titan

Apr 03, 2026
pulisher
Apr 03, 2026

Vertex Pharmaceuticals Inc (VX1.MU) Stock Forum & Discussion - Yahoo! Finance Canada

Apr 03, 2026
pulisher
Apr 03, 2026

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Growth and Technical Setup - ChartMill

Apr 03, 2026
pulisher
Apr 03, 2026

Aberdeen Group Reduces Stake in Vertex Pharmaceuticals - National Today

Apr 03, 2026
pulisher
Apr 03, 2026

Aberdeen Group plc Has $118.81 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Apr 03, 2026
pulisher
Apr 03, 2026

Vertex Pharmaceuticals Incorporated (VRTX) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 03, 2026
pulisher
Apr 02, 2026

Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance

Apr 02, 2026
pulisher
Apr 02, 2026

[ARS] VERTEX PHARMACEUTICALS INC / MA SEC Filing - stocktitan.net

Apr 02, 2026
pulisher
Apr 02, 2026

Vertex (NASDAQ: VRTX) posts $12B 2025 revenue and sets 2026 proxy votes - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

Vertex Pharmaceuticals: Label Expansions For ALYFTREK & TRIKAFTA Plus Strong Demand (VRTX) - Seeking Alpha

Apr 02, 2026
pulisher
Apr 02, 2026

Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday - AOL.com

Apr 02, 2026
pulisher
Apr 02, 2026

The Opioid Crisis Was an Innovation Failure. Vertex Just Showed a Way to Fix It - inc.com

Apr 02, 2026
pulisher
Apr 02, 2026

F&V Capital Management LLC Buys Shares of 3,645 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Apr 02, 2026
pulisher
Apr 02, 2026

Allspring Global Investments Holdings LLC Cuts Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Apr 02, 2026
pulisher
Apr 02, 2026

Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Banque Pictet & Cie SA - MarketBeat

Apr 02, 2026
pulisher
Apr 01, 2026

Vertex Advances FDA Filing for IgA Nephropathy Therapy - The Globe and Mail

Apr 01, 2026
pulisher
Apr 01, 2026

Vertex Pharmaceuticals (VRTX) Submits Biologics Licensing Application for Accelerated FDA Approval - GuruFocus

Apr 01, 2026
pulisher
Apr 01, 2026

Vertex Expands Cystic Fibrosis Reach As Kidney Drug Nears FDA Decision - Yahoo Finance

Apr 01, 2026
pulisher
Apr 01, 2026

Vertex Pharmaceuticals (NASDAQ: VRTX) reports 978-share Rule 144 resale and insider sales - Stock Titan

Apr 01, 2026
pulisher
Apr 01, 2026

FDA Expands Vertex (VRTX) Drugs' Usage for Cystic Fibrosis - GuruFocus

Apr 01, 2026
pulisher
Apr 01, 2026

Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval of Expanded Use of ALYFTREK (Vanzacaftor/Tezacaftor/Ivacaftor) - marketscreener.com

Apr 01, 2026
pulisher
Apr 01, 2026

Vertex Pharmaceuticals IncFDA expands indication for trikafta in cf patients ages 2 and older - marketscreener.com

Apr 01, 2026
pulisher
Apr 01, 2026

Vertex wins FDA label expansion for cystic fibrosis drugs - Seeking Alpha

Apr 01, 2026
pulisher
Apr 01, 2026

, Expanding Availability of These Medicines to ~95% of All People With CF in the United States - Business Wire

Apr 01, 2026
pulisher
Apr 01, 2026

Vertex Pharmaceuticals (VRTX): Company Profile, Stock Price, News, Rankings - Fortune

Apr 01, 2026
pulisher
Mar 31, 2026

Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Performance Indicators - Markets Mojo

Mar 31, 2026
pulisher
Mar 31, 2026

Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus

Mar 31, 2026
pulisher
Mar 31, 2026

Vertex (VRTX) CMO sells 2,329 shares in pre-set 10b5-1 trade - Stock Titan

Mar 31, 2026
pulisher
Mar 31, 2026

Vertex Pharmaceuticals Incorporated Completes Submission of Biologics Licensing Application for Povetacicept to the U.S. Food and Drug Administration - marketscreener.com

Mar 31, 2026
pulisher
Mar 31, 2026

[8-K] VERTEX PHARMACEUTICALS INC / MA Reports Material Event - Stock Titan

Mar 31, 2026
pulisher
Mar 31, 2026

Promising Biotech Stocks To Watch NowMarch 31st - MarketBeat

Mar 31, 2026
pulisher
Mar 31, 2026

Fierce Biotech Layoff Tracker 2026: Takeda plots 634 US job cuts - Fierce Biotech

Mar 31, 2026
pulisher
Mar 31, 2026

Boston Common Asset Management LLC Sells 20,952 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat

Mar 31, 2026
pulisher
Mar 30, 2026

Assessing Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness - simplywall.st

Mar 30, 2026
pulisher
Mar 30, 2026

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Mar 30, 2026
pulisher
Mar 30, 2026

VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 30, 2026
pulisher
Mar 30, 2026

Vertex’s VX-407 Contraceptive Interaction Study Reaches Completion: What Investors Should Watch - TipRanks

Mar 30, 2026
pulisher
Mar 30, 2026

BMO reiterates Vertex stock Outperform on cystic fibrosis strength By Investing.com - Investing.com UK

Mar 30, 2026
pulisher
Mar 29, 2026

Best Biotech Stocks To Watch TodayMarch 29th - MarketBeat

Mar 29, 2026
pulisher
Mar 28, 2026

Vertex Pharmaceuticals Stock Falls 4.6% After FDA Label Warning Hits Alyftrek, Trikafta - TechStock²

Mar 28, 2026
pulisher
Mar 28, 2026

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment - ChartMill

Mar 28, 2026
pulisher
Mar 28, 2026

Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550 - Insider Monkey

Mar 28, 2026
$760.27
price down icon 0.36%
$765.43
price up icon 2.30%
$319.52
price down icon 3.28%
$163.03
price down icon 0.48%
ONC ONC
$303.82
price up icon 0.44%
Kapitalisierung:     |  Volumen (24h):